Cargando…

Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades Which Alter Therapy Response

The Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades are often activated by genetic alterations in upstream signaling molecules such as receptor tyrosine kinases (RTK). Certain components of these pathways, RAS, NF1, BRAF, MEK1, DUSP5, PP2A, PIK3CA, PIK3R1, PIK3R4, PIK3R5, IRS4, AKT, NFKB1, MTOR, PTE...

Descripción completa

Detalles Bibliográficos
Autores principales:	McCubrey, James A., Steelman, Linda S., Chappell, William H., Abrams, Stephen L., Montalto, Giuseppe, Cervello, Melchiorre, Nicoletti, Ferdinando, Fagone, Paolo, Malaponte, Grazia, Mazzarino, Maria C., Candido, Saverio, Libra, Massimo, Bäsecke, Jörg, Mijatovic, Sanja, Maksimovic-Ivanic, Danijela, Milella, Michele, Tafuri, Agostino, Cocco, Lucio, Evangelisti, Camilla, Chiarini, Francesca, Martelli, Alberto M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2012
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3660063/ https://www.ncbi.nlm.nih.gov/pubmed/23006971

Ejemplares similares

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance
por: McCubrey, James A., et al.
Publicado: (2012)

Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging
por: Steelman, Linda S., et al.
Publicado: (2011)

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health
por: Chappell, William H., et al.
Publicado: (2011)

Influences of TP53 and the anti-aging DDR1 receptor in controlling Raf/MEK/ERK and PI3K/Akt expression and chemotherapeutic drug sensitivity in prostate cancer cell lines
por: Chappell, William H., et al.
Publicado: (2020)

Advances in Targeting Signal Transduction Pathways
por: McCubrey, James A., et al.
Publicado: (2012)

Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention
por: Davis, Nicole M., et al.
Publicado: (2014)

Effects of Ectopic Expression of NGAL on Doxorubicin Sensitivity
por: Chappell, William H., et al.
Publicado: (2012)

Multifaceted roles of GSK-3 and Wnt/β-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention
por: McCubrey, J A, et al.
Publicado: (2014)

Cancer therapy and treatments during COVID-19 era
por: Akula, Shaw M., et al.
Publicado: (2020)

Targeting GSK3 and Associated Signaling Pathways Involved in Cancer
por: Duda, Przemysław, et al.
Publicado: (2020)

GSK-3 as potential target for therapeutic intervention in cancer
por: McCubrey, James A., et al.
Publicado: (2014)

Cooperative Effects of Akt-1 and Raf-1 on the Induction of Cellular Senescence in Doxorubicin or Tamoxifen Treated Breast Cancer Cells
por: Taylor, Jackson R., et al.
Publicado: (2011)

Analysis of the B-RAF(V600E) mutation in cutaneous melanoma patients with occupational sun exposure
por: CANDIDO, SAVERIO, et al.
Publicado: (2014)

GSK-3β Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals
por: Abrams, Stephen L., et al.
Publicado: (2021)

Targeted therapy for hepatocellular carcinoma: novel agents on the horizon
por: Cervello, Melchiorre, et al.
Publicado: (2012)

Roles of GSK-3 and microRNAs on epithelial mesenchymal transition and cancer stem cells
por: McCubrey, James A., et al.
Publicado: (2016)

Novel Combination of Sorafenib and Celecoxib Provides Synergistic Anti-Proliferative and Pro-Apoptotic Effects in Human Liver Cancer Cells
por: Cervello, Melchiorre, et al.
Publicado: (2013)

The Role of GSK-3 in Cancer Immunotherapy: GSK-3 Inhibitors as a New Frontier in Cancer Treatment
por: Augello, Giuseppa, et al.
Publicado: (2020)

Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs
por: McCubrey, James A., et al.
Publicado: (2017)

Nectin like-5 overexpression correlates with the malignant phenotype in cutaneous melanoma
por: Bevelacqua, Valentina, et al.
Publicado: (2012)

Cytotoxic activity of the novel small molecule AKT inhibitor SC66 in hepatocellular carcinoma cells
por: Cusimano, Antonella, et al.
Publicado: (2014)

Effects of TP53 Mutations and miRs on Immune Responses in the Tumor Microenvironment Important in Pancreatic Cancer Progression
por: McCubrey, James A., et al.
Publicado: (2022)

Targeting signaling and apoptotic pathways involved in chemotherapeutic drug-resistance of hematopoietic cells
por: Abrams, Stephen L., et al.
Publicado: (2017)

Effects of the Mutant TP53 Reactivator APR-246 on Therapeutic Sensitivity of Pancreatic Cancer Cells in the Presence and Absence of WT-TP53
por: Abrams, Stephen L., et al.
Publicado: (2022)

The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients
por: Martelli, Alberto M., et al.
Publicado: (2010)

Therapeutic Targeting of mTOR in T-Cell Acute Lymphoblastic Leukemia: An Update
por: Evangelisti, Camilla, et al.
Publicado: (2018)

New landscapes and horizons in hepatocellular carcinoma therapy
por: Cervello, Melchiorre, et al.
Publicado: (2020)

Drug-resistance in doxorubicin-resistant FL5.12 hematopoietic cells: elevated MDR1, drug efflux and side-population positive and decreased BCL2-family member expression
por: Steelman, Linda S., et al.
Publicado: (2017)

Exploiting p53 Status to Enhance Effectiveness of Chemotherapy by Lowering Associated Toxicity
por: Steelman, Linda S., et al.
Publicado: (2011)

NUPR1, a new target in liver cancer: implication in controlling cell growth, migration, invasion and sorafenib resistance
por: Emma, M R, et al.
Publicado: (2016)

The Emerging Role of the Phosphatidylinositol 3-Kinase/ Akt/Mammalian Target of Rapamycin Signaling Network in Cancer Stem Cell Biology
por: Martelli, Alberto M., et al.
Publicado: (2010)

The Unfolded Protein Response: A Novel Therapeutic Target in Acute Leukemias
por: Martelli, Alberto M., et al.
Publicado: (2020)

Pathobiology and Therapeutic Relevance of GSK-3 in Chronic Hematological Malignancies
por: Martelli, Alberto M., et al.
Publicado: (2022)

Computational Modeling of PI3K/AKT and MAPK Signaling Pathways in Melanoma Cancer
por: Pappalardo, Francesco, et al.
Publicado: (2016)

Involvement of Akt-1 and mTOR in Sensitivity of Breast Cancer to Targeted Therapy
por: Sokolosky, Melissa L., et al.
Publicado: (2011)

MMP-9 overexpression is associated with intragenic hypermethylation of MMP9 gene in melanoma
por: Falzone, Luca, et al.
Publicado: (2016)

Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment
por: Martelli, Alberto M., et al.
Publicado: (2012)

PI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors
por: Lonetti, Annalisa, et al.
Publicado: (2015)

Therapeutic targeting of CK2 in acute and chronic leukemias
por: Buontempo, F, et al.
Publicado: (2018)

The PI3K/Akt/mTOR pathway: A potential pharmacological target in COVID-19
por: Basile, Maria Sofia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_p4u6r5hklr0p3477ggt16j70bt